ESC 365 - Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial

ESC Professional Premium Access

Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial

Session: State-of-the art treatment of HFmrEF and HFpEF in 2023

Topic: Treatment

Speaker: Doctor J. Butt (Copenhagen, DK)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Jawad Haider Butt

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

1 presentation

0 follower

3 more presentations in this session

State-of-the-art lecture on treatment of HFmrEF and HFpEF in 2023: insights from RCTs

Speaker: Professor L. Kober (Copenhagen, DK)

Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial

Speaker: Doctor A. Peikert (Graz, AT)

Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER

Speaker: Doctor X. Wang (Boston, US)

Access the full session

State-of-the art treatment of HFmrEF and HFpEF in 2023

Speakers: Doctor J. Butt, Professor L. Kober, Doctor A. Peikert, Doctor X. Wang

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources